Affimed is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapy treatments for cancer

The company's proprietary platform harnesses the power of the immune system by designing next-generation bispecific antibodies that can specifically target and engage immune cells to attack and eliminate tumor cells. Affimed aims to create highly effective, targeted therapies that not only improve patient outcomes but also enhance the overall treatment experience, working on various candidates in its pipeline to advance the future of cancer care.